You are here

Sanofi

Sanofi CEO turns to 'cobots' and AI to zap manufacturing costs

Sanofi CEO turns to 'cobots' and AI to zap manufacturing costs

Fierce Pharma

drug manufacturing

artificial intelligence

Flag link:

Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent

Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent

Yahoo/Zacks.com

Flag link:

Leo's Dupixent rival hits all endpoints in pivotal program

Leo's Dupixent rival hits all endpoints in pivotal program

Fierce Biotech

atopic dermatitis

Flag link:

Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both

Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both

Motley Fool

immuno-oncology

Flag link:

Sanofi CEO Hudson backs away from struggling diabetes, cardiovascular areas in strategy unveiling

Sanofi CEO Hudson backs away from struggling diabetes, cardiovascular areas in strategy unveiling

Fierce Pharma

cardiovascular death

Flag link:

ASH: Sanofi eyes FDA filing as orphan blood drug hits late-phase goal

ASH: Sanofi eyes FDA filing as orphan blood drug hits late-phase goal

Fierce Biotech

clinical trials

cold agglutinin disease

Flag link:

Sanofi says Dupixent could be a $10 billion drug, aims to sell Cialis and Tamiflu over the counter

Sanofi says Dupixent could be a $10 billion drug, aims to sell Cialis and Tamiflu over the counter

Stat

Flag link:

Sanofi to acquire Synthorx for $2.5 billion

Sanofi to acquire Synthorx for $2.5 billion

Marketwatch

Flag link:

Sanofi trades Seprafilm unit to Baxter for $350M in cash ahead of strategy launch

Sanofi trades Seprafilm unit to Baxter for $350M in cash ahead of strategy launch

Fierce Biotech

Flag link:

Which asthma biologic do docs prefer? It's not that simple: analyst

Which asthma biologic do docs prefer? It's not that simple: analyst

Fierce Pharma

Flag link:

Sanofi's strategy head to retire by month end, as company gears up for December strategic update

Sanofi's strategy head to retire by month end, as company gears up for December strategic update

Endpoints

Mazammil Mansuri

Flag link:

Sanofi weighing options for consumer healthcare unit: sources

Sanofi weighing options for consumer healthcare unit: sources

Reuters

consumer healthcare

Flag link:

Sanofi cuts chemical, water use in switch to continuous manufacturing

Sanofi cuts chemical, water use in switch to continuous manufacturing

Supply Chain Dive

drug manufacturing

continuous manufacturing

Flag link:

Top execs from AstraZeneca, Roche, Sanofi and GSK tout China investments at import expo

Top execs from AstraZeneca, Roche, Sanofi and GSK tout China investments at import expo

Fierce Pharma

Flag link:

Takeda's dengue shot 80% effective in massive phase 3 test

Takeda's dengue shot 80% effective in massive phase 3 test

Fierce Pharma

clinical trials

Flag link:

Sanofi’s Fluzone quadrivalent formulation gets FDA nod in older people

Sanofi’s Fluzone quadrivalent formulation gets FDA nod in older people

Pharmaceutical Business Review

Fluzone Quadrivalent

Flag link:

Sanofi shows off positive PhIII trial results for Toujeo, opening the door to a new group of diabetes patients

Sanofi shows off positive PhIII trial results for Toujeo, opening the door to a new group of diabetes patients

Endpoints

clinical trials

type 1 diabetes

Flag link:

Dupixent's already a blockbuster, but there's much more to come: Sanofi exec

Dupixent's already a blockbuster, but there's much more to come: Sanofi exec

Fierce Pharma

atopic dermatitis

Flag link:

Sanofi pays $315 million to settle Lemtrada go-slow claims

Sanofi pays $315 million to settle Lemtrada go-slow claims

Biopharma Dive

multiple sclerosis

Flag link:

Sanofi 3Q Net Profit Tumbles, Sales Rise Ahead of Forecasts

Sanofi 3Q Net Profit Tumbles, Sales Rise Ahead of Forecasts

Morningstar

Flag link:

Pages